HOME >> BIOLOGY >> NEWS
Once weekly ENBREL significantly reduced rheumatoid arthritis pain, inflammation & improved function

THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., June 19, 2003 - Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that patients receiving ENBREL(R) (etanercept) 50 mg once weekly for the treatment of active rheumatoid arthritis (RA) in a new clinical study experienced significant improvements in function and pain that were comparable to those receiving the currently approved dose (25 mg twice weekly), and significantly better than those receiving placebo. The data were presented at the European League Against Rheumatism (EULAR) Annual Congress of Rheumatology in Lisbon, Portugal.

The multi-center, double-blind, placebo-controlled study randomized 434 patients based on a 4:3:1 allocation to receive either ENBREL 50 mg (2 x 25 mg doses) once weekly, ENBREL 25 mg twice weekly, or placebo for eight weeks. The primary endpoint, a 20 percent improvement in signs and symptoms of RA (known as an ACR 20 response) after eight weeks, was achieved by 50 percent of patients treated once weekly with ENBREL, 49 percent of patients treated twice weekly with ENBREL and 19 percent of patients in the placebo group. Patients' functional status was assessed using the Health Assessment Questionnaire (HAQ). In addition, patient-reported measures assessing global status and pain were evaluated.

At week eight, improvement in HAQ was comparable for patients receiving either ENBREL dose, and significantly better than patients receiving placebo.

The average improvement from baseline in pain as reported by patients with ENBREL once weekly (33.4%) and ENBREL twice weekly (27.0%) was comparable, and higher than placebo (-19.3%). Average improvement from baseline in patient global scores showed similar results with ENBREL once weekly (26.8%), ENBREL twice weekly (26.7%) versus placebo (0.2%).

Adverse events, such as injection site reactions, infections, and headache, were similar to those reported in previous clinical tr
'"/>

Contact: Rebecca Hamm, Amgen
805-447-3872
Porter Novelli
20-Jun-2003


Page: 1 2 3 4

Related biology news :

1. ENBREL provided rapid and significant relief for psoriasis patients in second pivotal study
2. ENBREL rapidly, significantly improved back pain, mobility, function in ankylosing spondylitis
3. ENBREL combo therapy inhibits joint damage progression, offers significant RA symptom relief
4. ENBREL is first therapy approved for psoriatic arthritis
5. New Phase 2 study shows ankylosing spondylitis patients respond to ENBREL (etanercept)
6. Phase 3 psoriatic arthritis data for ENBREL (etanercept) announced at a national scientific meeting
7. Rare mutations can significantly increase risk factor for heart disease
8. Cancer health risk significantly underestimated by EPAs ambient model estimates
9. Double mastectomies significantly lower risk of breast cancer in women who are genetically at risk
10. HAART therapy significantly prolongs survival in AIDS patients with central nervous system lymphoma
11. Cognitive abilities increase significantly with time in most prematurely born children

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/2/2019)... , ... January 31, 2019 ... ... research organization headquartered in Morrisville, NC, providing full, customizable clinical research services ... Inc. to support educational programs for early stage life science entrepreneurs in ...
(Date:1/25/2019)... ... 24, 2019 , ... Review methodology could negatively impact elderly, ... to grapple with prescription drug costs, a new Pioneer Institute study ... before deciding whether to contract with the Institute for Clinical and Economic Review ...
(Date:1/20/2019)... ... January 16, 2019 , ... January has been a record-breaking month ... Not only has the company already hosted several of its signature cooking classes and ... and Janssen Pharmaceuticals, later this month. , Since 2008, Lajollacooks4u’s team-building events have ...
Breaking Biology News(10 mins):
(Date:1/30/2019)... ... January 30, 2019 , ... In 2016, ... 5StarWines to promote and give recognition to producers whose work focuses entirely on ... takes place in Verona, Italy, contemporaneously to the 5StarWines blind tasting organized from ...
(Date:1/24/2019)... ... 2019 , ... Controlled Contamination Services is pleased to announce three exciting new ... valuable new team members will support its growing operation across the US and will ... its business. This addition will enable CCS to widen its reach and provide enterprise ...
(Date:1/24/2019)... ... January 22, 2019 , ... Outsourcing ... its own set of assumptions, and RFP creation and management generally requires manual ... like comparing apples to oranges. These challenges can ultimately lead to study start ...
(Date:1/21/2019)... ... January 21, 2019 , ... Microbial Discovery ... for the industrial and institutional cleaning market. MDG’s SporActiv liquid and powder product ... needs. Applications include odor control, floor and tile cleaners, carpets, drains, portable restroom ...
Breaking Biology Technology:
Cached News: